1. Introduction
===============

The degeneration of joint tissues and inflammatory microenvironment are primary characteristics of osteoarthritis (OA), which is the main reason of disability in older adults with decrement in work hours and daily life quality.^\[[@R1],[@R2]\]^ With a prevalence that increases with age, OA is clinically characterized by pain and stiffness of entire joint and reduced range of motion, reportedly 10% patients older than 55 years has symptomatic radiographic knee.^\[[@R3]\]^

Current treatments consist of physiotherapy, changes in lifestyle, and intake of drugs included opioids, analgesics, corticoids, COX-2 inhibitors, and nonsteroidal anti-inflammatory drugs.^\[[@R4]\]^ Hyaluronic acid (HA), as the most commonly used infiltrative therapy, is a natural component of soft connective tissue with the ability to restore the viscoelastic properties of the synovial fluid and joint lubrication. It also has antiapoptotic, anti-inflammatory, antiangiogenic, and antifibrotic properties.^\[[@R5]\]^ Polynucleotides (PNs), a mixture of purines, pyrimidines, deoxyribonucleotides, and deoxyribonucleosides, links water and have viscoelastic property but also induce cell growth, collagen production, migration of several cell types, and can reduce inflammation.^\[[@R6]--[@R8]\]^ In preclinical and clinical studies PNs have shown positive results in musculoskeletal tissue regeneration^\[[@R9]\]^ and reduction in proteoglycan degradation and in metalloproteinase activity.^\[[@R10]\]^

Currently, the clinical effectiveness of PNs and HA are ongoing debate, and no meta-analysis evaluated the effects of the combination of PNs and HA in OA. To further confirm the efficacy of combination of PNs and HA \[PNs associated with HA (PNHA)\], we performed this systematic review and meta-analysis to explore the clinical outcomes of them.

2. Methods
==========

2.1. Protocol registration
--------------------------

The protocol has been registered in PROSPERO, which is an International Prospective Register of Systematic Reviews. The registration number is CRD42020167678 (<http://www.crd.york.ac.uk/PROSPERO/>).^\[[@R11]\]^ The content of this protocol will follow the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) recommendations.^\[[@R12]\]^ We also plan to conduct it in accordance with the Cochrane Handbook for the systematic reviews of interventions and preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines.^\[[@R13]\]^

2.2. Eligibility criteria
-------------------------

### 2.2.1. Types of studies

Randomized controlled trial (RCT) without published year, publication status limitations.

### 2.2.2. Types of participants

Inclusion criteria required patients without pre-existing infiltrative therapies or patients with a single previous infiltration cycle, performed at least 6 months before enrollment. Exclusion criteria include pregnancy or breastfeeding, abuse of alcohol or drugs, systemic anticoagulants and steroids ongoing or suspended for less than 1 month, hematological diseases or local skin lesions in the site of treatment inoculation, patients with pre-existing infiltrative therapies or patients with a single previous HA infiltration cycle, performed less than 6 month before enrollment and Hypersensitivity to the therapeutic products, previous bone fractures, knee severe trauma, joint deformities, rheumatoid arthritis, articular inflammatory diseases, and previous surgery.

### 2.2.3. Types of interventions and comparators

1.  the study group, treated with intra-articular injection of PNHA and

2.  the control group, treated with intra-articular injection of HA.

### 2.2.4. Types of outcome measures

Outcomes were mainly identified by relevant literature and existed clinical practice. The evaluations of clinical function and pain were performed with the WOMAC score^\[[@R14]\]^ and knee society score^\[[@R15]\]^ at 0 and after 2, 6, and 12 months from the beginning of the treatments. Besides, all the endpoints reported in the included studies will be collected and evaluated, although we may not mention some of them in this protocol.

2.3. Literature search
----------------------

A systematic search of the literature will be conducted without language and year restrictions to identify all relevant RCT. We will search following electronic databases: PubMed, EMBASE and Cochrane Library from 2002 to May 2020 using related search terms, including "hyaluronic acid", "knee osteoarthritides," "osteoarth." In addition, congress and conference proceedings will be manually retrieved. Related articles and references of included research will also be tracked to find potential studies. If significant data was incomplete in included study, we will contact the authors to get unpublished data.

2.4. Study selection and data extraction
----------------------------------------

After imported into the Endnote X7 and duplication, retrieved records will be independently screened by 2 reviewers (LZ and NBL). First, we will read the titles and abstracts of all indentified records to exclude clearly unrelated records based on the inclusion criteria. Then the full texts of the articles retained were reviewed to further determine their suitability. Any disagreement will be resolved by a third reviewer (YBG or NZ). We will show the selection process in details in the PRISMA flow chart.

Two authors (RLC and CXY) of this review will independently extract the data using a pre-defined form. The basic characteristics, related outcome and quality evaluation information of included studies will be collected. Similarly, any discrepancies will be resolved by a third reviewer (YBG or NZ). Data extracted will include author, year, study type, number of participants, intervention, control, demographics, complications, previous history, the follow-up time and WOMAC score and knee society score.

2.5. Quality of evidence assessment
-----------------------------------

The quality of included studies will be assessed by grading of recommendations assessment development and evaluation (GRADE), and divided into 4 levels: high quality, moderate quality, low quality, and very low quality.^\[[@R16]\]^

2.6. Assessment of study bias
-----------------------------

Included study bias will be independently assessed by 2 reviewers (LZ and QL) and any disagreement will be solved by a third reviewer (YBG or NZ). For randomized controlled trials, we will use the Cochrane risk of bias tools to evaluate potential bias in 7 specific domains:

1.  sequence generation,

2.  allocation concealment,

3.  blinding of participants and personnel,

4.  blinding of outcome assessment,

5.  incomplete outcome data,

6.  selective outcome reporting,

7.  other bias.^\[[@R17]\]^

2.7. Statistical analysis
-------------------------

For dichotomous variables, The Relative Risk with 95% confidence intervals (CI) were calculated from each study. Continuous variables will be presented as Standard Mean Difference with 95% CI. All endpoints will be combined and performed meta-analysis by using DerSimonian and Laird random effects model.^\[[@R18]\]^ We assessed statistical heterogeneity by using Chi^2^ test and I^2^ statistic. We will consider significant heterogeneity when *P* \< .10 for Chi^2^ or I^2^ \> 50%.^\[[@R19]\]^ All primary analyses were performed with STATA v15.1 (Stata Corp, College Station, TX).

### 2.7.1. Subgroup analysis

We will also conduct subgroup analysis to find more potential information based on pre-set criteria in 4 variables:

1.  different patient age,

2.  different follow-up time.

### 2.7.2. Sensitivity analysis

If the heterogeneity is high, we will conduct sensitivity analyses based on the patient age and follow-up time.

### 2.7.3. Publication bias

The likelihood of publication bias was assessed graphically through the generation of funnel plots, evaluated using an Egger test.^\[[@R20]\]^

3. Results
==========

The study does not require ethical approval because the meta-analysis is based on published research and the original data are anonymous. And this study will eventually be published in a peer-reviewed journal in the form of a scientific paper.

4. Discussion
=============

To our knowledge, this is the first systematic review and meta-analysis concerning the efficacy of combination of PNs and HA \[PNs associated with HA (PNHA)\]. The results from our research may provide meaningful evidence for clinical practice and give a valuable reference for future study.

There seem to be some potential limitations for our study. First, we only include English language articles, which might miss some important data in other language article. In addition, only RCT and no cohort studies will be included in our study, which may have an obstacle to our data pooling and results interpretation. But it probably help to promotes several more reliable conclusions and focus on more precious direction for future clinical studies to some extent. Notwithstanding its limitation, we hope to provide a prompt and credible evaluation for efficacy of intra-articular PNHA vs HA alone in the treatment of knee osteoarthritis.
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